PMID- 20836961
OWN - NLM
STAT- MEDLINE
DCOM- 20100927
LR  - 20131121
IS  - 1603-6824 (Electronic)
IS  - 0041-5782 (Linking)
VI  - 172
IP  - 37
DP  - 2010 Sep 13
TI  - [Unfractionated heparin and low molecular weight heparin for acute coronary 
      syndromes--assessment of a Cochrane review].
PG  - 2522-6
AB  - In aspirin-treated patients with acute coronary syndromes without ST-segment 
      elevation unfractionated heparin (UFH) or low molecular weight heparin (LMWH) 
      treatment < 7 days significantly reduce the risk of acute myocardial infarction 
      (AMI), and LMWH furthermore reduces revascularisation. There is a non-significant 
      effect on mortality compared with placebo and an insignificantly increased risk 
      of haemorrhagic complications. No net clinical benefit of LMWH was found compared 
      to UHF, but LMWH has pharmacokinetic advantages. The optimal duration of heparin 
      treatment remains controversial.
FAU - Husted, Steen Elkjaer
AU  - Husted SE
AD  - Medicinsk-kardiologisk Afdeling, Arhus Sygehus, Arhus Universitets-horpital, 8000 
      Arhus C, Denmark. steehust@rm.dk
FAU - Nielsen, Hans Kraemmer
AU  - Nielsen HK
LA  - dan
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Ufraktioneret og lavmolekylaert heparin ved akutte koronare syndromer--en 
      gennemgang af et Cochrane-review.
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Evidence-Based Medicine
MH  - Fibrinolytic Agents/adverse effects/therapeutic use
MH  - Heparin/adverse effects/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - Venous Thromboembolism/prevention & control
RF  - 10
EDAT- 2010/09/15 06:00
MHDA- 2010/09/29 06:00
CRDT- 2010/09/15 06:00
PHST- 2010/09/15 06:00 [entrez]
PHST- 2010/09/15 06:00 [pubmed]
PHST- 2010/09/29 06:00 [medline]
AID - VP05090183 [pii]
PST - ppublish
SO  - Ugeskr Laeger. 2010 Sep 13;172(37):2522-6.